https://medicalscience.ascentage.com/
Ascentage Web Booth
webbooth
https://www.biospace.com/ascentage-pharma-s-mdm2-p53-inhibitor-apg-115-alrizomadlin-granted-an-orphan-drug-designation-by-the-fda-for-the-treatment-of-stage-iib-iv-melanoma-marking-the-twelfth-obtained-by-the-company
Ascentage Pharma's MDM2-p53 Inhibitor APG-115 (Alrizomadlin) Granted an Orphan Drug Designation by...
Jul 21, 2021 - Ascentage Pharma, a globally focused biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases,...
https://metrocitiesaba.com/ascentage-pharma-signs-option-agreement-with-takeda-to-enter-into-exclusive-global-license-for-olverembatinib-a-third-generation-bcr-abl-tyrosine-kinase-inhibitor-tki/
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for...
Jun 14, 2024 - Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. Ascentage Pharma...
https://www.surinamehealthcarepress.com/article/864041211-ascentage-pharma-to-present-data-from-multiple-studies-of-olverembatinib-including-the-first-dataset-from-polaris-1-study-at-ash-2025
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First...